Interpace Biosciences Announces New Real-world Data;

PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new real-world clinical utility data for their ThyGeNEXT^® + ThyraMIR^®v2 combination test platform to assess the malignancy risk of indeterminate thyroid nodules (ITN). The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119). The poster can also be viewed at www.thyroiddx.com/poster.

Clinical utility was determined within a prospectively collected, consecutive, real-world clinical cohort utilizing the ThyGeNEXT oncogene mutation panel and an earlier version of the Company’s microRNA (miRNA) risk classifier, ThyraMIR^®. A secondary, retrospective analysis was also performed with ThyraMIRv2, the Company’s new miRNA pairwise expression profiler.

The data supports that both versions of the test platform accurately risk-stratified ITNs. Additionally, a blinded analysis of pairwise miRNA expression profiling demonstrated improved accuracy from the original testing platform. A decrease in the false-positive rate and a high Benign Call Rate (BCR) of 70% were also demonstrated in this study, thereby allowing more patients to avoid potentially unnecessary surgery.

Dr. Syd Finkelstein, Chief Scientific Officer of Interpace Diagnostics, LLC added, “We are pleased that these independent clinical utility data further support the very strong effectiveness of miRNA pairwise expression profiling in risk-stratifying indeterminate thyroid nodules”.

Further commenting, President and CEO of Interpace Biosciences, Tom Burnell, PhD, stated “We remain committed to providing high-value molecular diagnostic tests that aid in…